The α7 nicotinic acetylcholine receptor (α7nAChR) has been a promising target for diseases affecting cognition and higher cortical functions; however, the effect observed in animal models failed to translate into human clinical trials identifying a translational gap. CHRFAM7A is a human-specific fusion gene with properties that enable incorporation into the α7nAChR and, being human specific, CHRFAM7A effect was not accounted for in preclinical studies. We hypothesized that CHRFAM7A may account for this translational gap and understanding its function may offer novel insights when exploring α7nAChR as a drug target. CHRFAM7A is present in different copy number variations (CNV) in the human genome with high frequency. To study the functional consequences of the presence of the CHRFAM7A, two induced pluripotent stem cell (iPSC) lines (0 copy and 1 copy direct) were developed. The 0 copy line was rescued with CHRFAM7A transfection to control for genetic heterogeneity. As readouts for genotype-phenotype correlation, α7nAChR synaptic transmission and amyloid beta 1-42 (Aβ 1-42 ) uptake were tested. Synaptic transmission in the presence of CHRFAM7A demonstrated that PNU-modulated desensitization of α7nAChR currents increased as a function of CHRFAM7A dosage. CHRFAM7A mitigated the dose response of Aβ 1-42 uptake suggesting a protective effect beyond physiological concentrations. Furthermore, in the presence of CHRFAM7A Aβ 1-42 uptake activated neuronal interleukin 1β (IL-1β) and tumor necrosis factor α (TNF-α) without activating the canonical inflammasome pathway. Lead optimization may identify more potent molecules when the screen has a model harboring CHRFAM7A. Incorporating pharmacogenetics into clinical trials may enhance signals in efficacy measures.
Introduction
The α7 nicotinic acetylcholine receptor (α7nAChR) is a ligand-gated ion channel implicated in cognition and neuropsychiatric disorders, including schizophrenia 1-3 , Alzheimer's disease (AD) 4, 5 attention deficit hyperactivity disorder 6 , addiction 7 , pain 8, 9 , and Parkinson disease 10 . Agonists and positive allosteric modulators (PAMs) of α7nAChR are being tested in clinical trials for central nervous system indications 11 , and a translational gap emerged 12 . While animal studies consistently demonstrate a cognitive benefit, this effect was not apparent in human trials 13, 14 .
The α7nAChR is a homopentamer characterized by unique functional properties, including fast activation and desensitization by agonists, high Ca 2+ permeability, and selective inhibition by α-bungarotoxin (α-BGT) and methyllycaconitine (MLA) 12, 15 . It is expressed in brain regions underlying cognition and memory 16 , including the basal forebrain (nucleus basalis), hippocampus, neocortex, and amygdala 17, 18 , α7nAChRs are expressed in neurons, microglia and astrocytes 19 . The α7nAChRs are regulators of the cholinergic anti-inflammatory pathway 20, 21 , and acetylcholine (ACh) produces a dose-dependent inhibition of interleukin 6 (IL-6), IL-1β, and tumor necrosis factor α (TNF-α) in human macrophages 22 . In neuronal cell culture, Aβ binds with high affinity to the α7nAChRs and the receptor facilitates internalization of Aβ 1-42 through endocytosis 23 .
One of the unique features of the α7nAChR in the human context is the presence of the fusion gene, CHRFAM7A 24, 25 , The ancestral allele lacking the fusion gene is present in about 1% of the population, while 99% of the human population harbors the fusion gene. Further complexity is added as the orientation of CHRFAM7A can be direct or inverted, and the gene itself can be present in 1, 2, or even 3 copies, allowing for homozygous and heterozygous combinations. The predicted proteins of the direct and inverted alleles differ due to a 2 bp deletion in the inverted sequence causing a frameshift during protein translation 26 .
CHRFAM7A harbors exons 5-10 of CHRNA7 (transmembrane and intracellular domain) and 5 new exons of the FAM7 sequence (extracellular domain) corresponding to a part-functional CHRNA7. Two independent copy number variation (CNV) genome-wide association studies (GWAS) reported an association between CHRFAM7A dosage and AD; lower copy number and lower expression levels of the fusion gene is associated with AD [27] [28] [29] , In contrast, in schizophrenia and bipolar disorder, upregulation of CHRFAM7A was observed in the brain 3 and association studies suggest a correlation with the inverted orientation (2 bp deletion) 26 . Despite its widespread implication in neuropsychiatric diseases, functional studies are sparse. In CHRFAM7A-transfected Xenopus oocytes, CHRFAM7A is a stoichiometric dominantnegative regulator of α7nAChR 30, 31 .
Owing to the high frequency and complexity of the CHRFAM7A CNV in the human population, understanding its functional impact is imperative for interpreting α7nAChR targeting clinical trials. To study the functional consequences of the presence of the CHRFAM7A gene product on α7nAChR, we developed two induced pluripotent stem cell (iPSC) lines from skin biopsies of subjects affected by AD. UB068 has two ancestral haplotypes, thus it is lacking the CHRFAM7A gene (0 copy). UB052 has the CHRFAM7A direct orientation haplotype on one allele and the ancestral haplotype on the other allele (1 copy). iPSCs differentiated into relevant cell types, in our case medial ganglionic eminence (MGE) progenitors and neurons, model the effect of CHRFAM7A on α7nAChR function in the human context. As readouts for genotype-phenotype correlation, α7nAChR synaptic transmission and Aβ 1-42 uptake were tested.
Materials and methods

Ethical statement, skin biopsy, and genotyping
The Institutional Review Board approved the study. The informed consents were obtained from the donors. Subjects requiring legally authorized representatives were excluded from the study.
iPSC generation and cell culture iPSC lines (UB068-0 copy and UB052-1 copy direct) were generated from human skin biopsies in WNYSTEM (University at Buffalo) by episomal transformation and propagated in standard media (Supplementary data, Methods). iPSCs characterization according the industry standards included morphological assessment and live staining with the TRA-1-60 Alexa Fluor 488 Conjugate Kit (Life Technologies). Gene and protein expression for pluripotency/self-renewal and the three germ layer markers at gene and protein levels was assessed by reverse transcription-quantitative polymerase chain reaction (RT-qPCR) and immunocytochemistry (ICC) (Supplementary data, Methods; The primers (IDT) are listed in Supplementary data, Table 1 , The primary antibodies are listed in Supplementary data, Table 2 ). Array comparative genome hybridization (aCGH) was performed between the iPSC colony and the original blood DNA sample from the same individual according to the manufacturer's protocol. The ADM2 algorithm with a threshold of 6 was used to detect de novo events.
Pluripotency of the iPSC was confirmed by the TaqMan hPSC Scorecard Assay (Life Technologies) according to the manufacturer's protocol 32, 33 .
Neuronal differentiation and transfection
Neuronal differentiation of iPSC toward MGE progenitors and neurons was carried out using the protocol based on Liu et al. 34 with modifications (Supplementary data, Methods). MGE progenitors were transfected with either pcDNA3.1-CHRFAM7A-mCherry (a gift from Henry Lester (Addgene plasmid # 62635) 35 ) or with pcDNA3.3-mCherry (a gift from Derrick Rossi (Addgene plasmid # 26823) 36 constructs according to Ma et al. 37 .
Total cell lysate preparation and immunoblotting
Total cell lysates from MGE progenitors were prepared using RIPA buffer (Cell Signaling Technologies) according to the manufacturer's protocol. Twenty-five μg of total protein was separated on 4-20% sodium dodecyl sulfate-polyacrylamide gel electrophoresis (Bio-Rad), transferred onto polyvinylidene difluoride membrane (Bio-Rad), and incubated overnight at 4°C with primary antibodies (Supplementary data, Table 2 ). Specific immunoreactive bands were detected using ChemiDoc XRS + Imaging Systems (Bio-Rad).
α-BGT staining and confocal microscopy
Live α-BGT staining of neurons was carried out as described previously 38 . Briefly, neurons grown on 8-well glass chambers were pre-incubated for 10 min with 1 mM Nicotine followed by incubation for 30 min with 2 μM with α-BGT. Confocal images were captured by using LSM510 Meta microscope (×40 objective). Images were acquired using the ZEN black software (Zeiss).
HEK 293 cell culture and transfection
Human embryonic kidney (HEK) 293 cells were maintained in Dulbecco's Minimal Essential Medium supplemented with 10% fetal bovine serum and 1% penicillin-streptomycin, pH 7.4. Human α7nAChRs and CHRFAM7A were expressed in HEK 293 cells by transient transfection (CaPO 4 precipitation method) of these cDNA in ratios of 4:1 or 1:4. To aid surface expression of α7, we co-transfected intracellular chaperones Ric-3 39 and NACHO 40 in 1:1:1 ratio in all experiments.
Electrophysiology
Whole-cell and single-channel currents were recorded in the cell-attached patch configuration as described previously 41 (Supplementary data, Methods). Kinetic analyses of single-channel currents were performed by using QuB 42 . Single-channel currents were idealized by segmental k-means algorithm. nPo was estimated by dividing the cumulative open probability by the number of channels in the patch (maximum number of overlaps of open current levels in the data) as follows:
Amyloid beta uptake and quantification Amyloid beta uptake was performed using fluorescently labeled Aβ 1-42 (AnaSpec) as described previously 43 . Briefly, MGE progenitors grown on glass coverslips were treated with various concentrations of Fluorescin-Aβ (1, 10, 25, 50, 100, and 250 nM) for 18 h. Live images were taken using EVOS (Life Technologies) microscope (×40 objective). Confocal images were taken with the LSM510 Meta microscope (×40 objective). Amyloid beta uptake was quantified by using ImageJ (imagej.nih.gov) or by Flow cytometry using LSRII-Fortessa with FACS DIVA (BD Biosciences). The flow cytometry data were analyzed using the FlowJo software (https://www.flowjo.com/). Data are presented as the average of triplicates ± standard deviation (SD).
IL-1β enzyme-linked immunosorbent assay (ELISA)
Following transfection and amyloid beta uptake, total cell lysates were collected and stored at −80°C. Concentration of IL-1β in the cell lysates was estimated using a human-specific high-sensitivity IL-1β ELISA Kit (Thermo Fisher) according to the manufacturer's protocol.
Statistical analysis
Values are expressed as means ± SD or ±SEM, as indicated in figure legends. Statistical significance was determined by an unpaired Student's t-test (two-tailed). P values <0.05 were deemed statistically significant.
Results
iPSC characterization
Stem cell characteristics of new iPSC lines UB068 (0 copy) and UB052 (1 copy) were confirmed by morphology; TRA1-60 live cell staining ( Fig. 1a ); detecting expression of pluripotency/self-renewal markers (NANOG, OCT-4, and SOX2) ( Fig. 1b) ; and by ICC for Nanog, Oct-4, SOX2 and SSEA-4 ( Fig. 1c ). aCGH between the iPSC colony and the original blood DNA excluded de novo chromosomal aberrations and CNVs ( Fig. 1a , Supplementary data). TaqMan assay specific to the breakpoint sequence confirmed CHRFAM7A CNV dosage ( Fig. 1b, Supplementary data) .
Pluripotency of iPSC lines was confirmed by embryoid body (EB)-based non-directed differentiation ( Fig. 1c , Supplementary data), gene expression ( Fig. 1d ), and ICC with anti-βIII-tubulin (ectoderm), anti-α-SMA (mesoderm), and anti-α-fetoprotein (AFP, endoderm) antibodies ( Fig. 1e ) and by the TaqMan hPSC Scorecard Assay (ThermoFisher) ( Fig. 1d , Supplementary data).
Neuronal differentiation
Based on the TaqMan hPSC Scorecard Assay clones with the highest preference for neuronal differentiation (UB068, clone 2 and UB052, clone 2) were chosen for further experiments. UB068 (0 copy) and UB052 (1 copy) clones were differentiated into MGE progenitors 34 and MGE-derived BFCNs and GABA interneurons. Expression levels of NKX2.1, LHX6, and LHX8 (MGE markers), FOXG1 (forebrain marker), PAX6 (dorsal forebrain marker) SOX2 and MAP-2 (pan neuronal markers), and ChAT, GAD, TH, and HB9 (BFCN, GABA, dopaminergic, and motor neuron markers, respectively) were quantified during neuronal differentiation ( Fig. 2a , Supplementary data). MGE progenitors demonstrated high level of FOXG1, NKX2.1, LHX6, and LHX8 expression detected at D25 and MGE-derived GABA and BFCN showed high level of GAD and ChAT expression and very low level of TH and HB9 expression at D40. ICC confirmed GABA and/or choline acetyltransferase (ChAT) expression in neurons ( Fig. 2b, Supplementary data ). Spontaneous action current activity and voltage-gated Na+ and K+ currents recorded from UB068-and UB052-derived neuronal cultures confirmed functional neurons ( Fig. 2c , Supplementary data). Single-channel patch-clamp analysis confirmed α7-specific currents in neurons ( Fig. 2d , Supplementary data). Fig. 2b ) and MGE-derived neurons (both BFCN and GABA interneurons) generated from UB068 and UB052 lines ( Fig. 2b ). Live staining with α-BGT demonstrated the presence of functional α7nAChR in both UB068-and UB052-derived neurons (Fig. 2c ).
CHRFAM7A gene expression during neuronal differentiation
CHRFAM7A is a modulator of the α7nAChR
The effect of CHRFAM7A on α7nAChRs can be attributed to altered biophysical properties and/or surface expression of the channels. To investigate the possible changes in the kinetic properties of α7nAChRs, singlechannel cell-attached (mechanism of action) and wholecell patch-clamp (surface expression) recordings on UB068 and UB052 neurons were performed.
Functional expression of neuronal α7nAChRs was studied by recording cell-attached single-channel currents Comparative nPo analyses of currents from both cell types showed the differences in CHRFAM7A effects on the channel kinetic properties (Fig. 3c) .
To probe the effect of CHRFAM7A on α7nAChR stoichiometry and functional properties, we heterologously expressed them by transfecting CHRNA7 and CHRFAM7A cDNA in HEK 293 cells in 4:1 and 1:4 proportions. The dosage of cDNA was expected to determine the stoichiometry of the α7nAChR expressed in HEK 293 cells. PNU modulated currents from HEK 293 cells expressing α7nAChR and CHRFAM7A both in 4:1 and 1:4 ratios (Fig. 3b, left and right panels respectively) . Qualitatively, the single-channel current clusters appeared Confocal images demonstrating expression of CHRNA7/CHRFAM7A in MGE progenitors (NKX 2.1), GABA interneurons (GABA), and BFCN (choline acetyltransferase). Note that CHRNA7 and CHRMFAM7A cannot be distinguished with antibodies. c α7nAChR (α7 nicotinic acetylcholine receptor)specific live staining of UB068-and UB052-derived neurons with α-bungarotoxin (α-BGT). Preincubation with nicotine prevents fluorescein isothiocyanate-α-BGT binding similar in both cases. However, nPo analyses of both currents suggest that desensitization of PNU-modulated α7nAChR currents increased as a function of CHRFAM7A dosage (Fig. 3d) , consistent with the results contrasting UB068 and UB052.
Amyloid beta uptake via the α7nAChR is mitigated by CHRFAM7A Aβ 1-42 uptake in MGE progenitors derived from UB068 (0 copy), and UB052 (1 copy) lines was quantified by cell counts (live EVOS and confocal images, ImageJ) and flow cytometry. The results demonstrated higher Fluorescin-Aβ 1-42 uptake in UB068 in contrast to UB052 (Fig. 4a ). Furthermore, while the uptake was dose dependent (correlating with increasing concentration of Fluorescin-Aβ 1-42 from 1 to 250 nM) in UB068, it was constant between concentrations of 25-250 nM in UB052 (Fig. 4a ). This suggests that CHRFAM7A may be functioning as a regulator of Aβ 1-42 uptake beyond physiological concentrations.
Pharmacological modulation of the α7nAChR affected Aβ 1-42 uptake suggesting an α7AChR-dependent mechanism. Pretreatment of MGE progenitors with the α7-selective antagonist MLA resulted in a significant decrease in Aβ 1-42 uptake in neuronal progenitor cells (NPCs) derived from UB068 (from 74 to 43%; P = 0.009) and from UB052 (from 58 to 44%; P = 0.037) (Fig. 4b ).
To exclude that the observed effect is caused by the different genetic background in the two lines, UB068derived NPCs were transfected with pcDNA3.1-CHRFAM7A-mCherry cDNA (controls: pcDNA3.3-mCherry empty vector (EV)). Efficiency of transfection was estimated by counting mCherry-positive cells and confirmed by qPCR with specific primers (Fig. 3 , Supplementary data). After 24 h of transfection, the cells were treated for 18 h with the concentration gradient of Fluorescin-Aβ 1-42 (1-250 nM) . Aβ 1-42 uptake demonstrated that the presence of CHRFAM7A leads to a decrease in Aβ 1-42 uptake (Fig. 4c ). Furthermore, the regulatory effect of CHRFAM7A on Aβ 1-42 uptake observed in UB052-derived NPCs between the concentrations from 25 to 250 nM was replicated. In contrast, transfection of the NPC with EV pcDNA3.3-mCherry resulted in a dose-response Aβ 1-42 uptake similar to nontransfected UB068. Orthogonal quantification by flow cytometry corroborated these results ( Fig. 4d and Fig. 4 , Supplementary data).
Activation of inflammatory pathways by Aβ 1-42 through the α7nAChR is mitigated by CHRFAM7A
α7nAChRs are regulators of the cholinergic antiinflammatory pathway and ACh produces a dosedependent inhibition of IL-6, IL-1β, and TNF-α in macrophages. Therefore, we examined whether this mechanism plays a role in MGE progenitors expressing α7AChRs and whether it is modulated by the presence of CHRFAM7A. We hypothesized that the presence of CHRFAM7A affects the inflammatory pathways activated by Aβ 1-42 uptake. We found that expression levels of IL-1B and TNFA are increased in MGE progenitors expressing CHRFAM7A (UB052 and UB068 transfected with CHRFAM7A; Fig. 5a -left and right panels), whereas CAS-1 and CAS-8 expression are higher in MGE progenitors lacking the fusion gene (UB068 and transfection with EV) suggesting that IL-1β activation in the presence of CHRFAM7A is not dependent on the canonical inflammasome pathway. ΝFΚΒ is not affected by the presence of CHRFAM7A (Fig. 5a-left and right panels) . Pretreatment of NPCs with MLA (24 h) followed by Fluorescin-Aβ 1-42 uptake (100 nM; 18 h) significantly decreased Aβ 1-42 -activated expression of IL-1B (Fig. 5b , left panel) and TNFA (Fig. 5b, right panel) in both lines suggesting an α7nAChR-dependent mechanism. Furthermore, Fluorescin-Aβ 1-42 uptake increased expression of IL-1β and TNF-α in a concentration-dependent manner in CHRFAM7A-transfected cells but not in EV-transfected cells (Fig. 5c, left and right panels) . The CHRFAM7A-dependent increase in IL-1β expression was validated by ICC ( Fig. 5d ) and immunoblotting (Fig. 5e ). ELISA demonstrated that IL-1β is released from the cells and that the presence of CHRFAM7A causes a dosedependent IL-1B release in response to Fluorescin-Aβ 1-42 uptake (Fig. 5f ).
Discussion
Human-specific genes are emerging culprits in complex human diseases 46 . CHRFAM7A, a human specific fusion gene in high frequency in the population, has been implicated in a broad array of neuropsychiatric disorders, including schizophrenia, bipolar disorder, dementia with Lewy bodies, Pick disease, and AD; all are human-specific diseases affecting association cortices and higher cognitive function 25 . While CHRN7A has been a promising target for diseases affecting cognition, the effect observed in animal models failed to translate in human clinical trials suggesting a human-specific mechanism 13,14 , we developed a model system to study the modifying effect of CHRFAM7A which (i) has the human biological context, (ii) allows studies in specific cell types, (iii) is a renewable source, and iv) is amenable to scaling. Adapting this iPSC system for high-throughput screening can advance drug discovery in diseases such as AD and schizophrenia and addresses unmet medical needs. In this work, we present two iPSC lines, one with the rare homozygous ancestral haplotype with no CHRFAM7A and another harboring a single direct copy of CHRFAM7A on one allele with the ancestral haplotype on the other. The CHRFAM7A CNV harboring iPSC line contrasted to the 0 copy state provides a unique experimental system, where its effect can be studied in disease-relevant differentiated cells. While the two lines are from two different individuals, transfection of the CHRFAM7A into the 0 copy line showed similar results when the transfection efficiency is taken into account, suggesting that the results are independent of the genetic background. There is a need for genomeedited isogenic lines, such as UB068 with inserted CHRFAM7A, and UB052 with knocking out CHRFAM7A to address CHRFAM7A effect on α7nAChR function. iPSC lines underwent stringent characterization and selected colonies were successfully differentiated into MGE progenitors. CHRNA7 and CHRFAM7A expression increases with differentiation, and CHRFAM7A is preferentially induced when present in the cell line. Functional receptors demonstrated electrophysiological properties and response to pharmacological treatments with agonists, antagonists, and PAMs consistent with α7nAChR.
Interestingly, when CHRFAM7A was present either in the iPSC line UB052 or after transfection of HEK293 cells, electrophysiological properties of α7nAChR were different from the 0 copy line. PNU in UB068 cells (CHRFAM7A absent) progressively increased channel open probability of single α7nAChRs in a time-dependent manner 44 . On the other hand, in UB052, PNU-modulated currents ran down faster than in UB068. Comparative nPo analyses of currents from both cell types showed clear difference in kinetic properties whether CHRFAM7A was expressed or absent. When CHRNA7 and CHRFAM7A cDNA in HEK 293 cells were expressed in 4:1 and 1:4 proportions, PNU modulated currents differentially. Qualitatively, the single-channel current clusters appeared similar in both cases; however, nPo analyses of both currents suggest that desensitization of PNU-modulated α7nAChR currents increased as a function of CHRFAM7A dosage. These altered electrophysiological properties could suggest that, based on their genotype, individuals may respond differentially to PAMs and perhaps to agonists and antagonists as well. Thus, during drug development by targeting α7nAChR for indications such as cognition or negative symptoms of schizophrenia, taking into account these pharmacogenetic correlations may prove more powerful.
CHRFAM7A modified Aβ 1-42 uptake mediated through the α7nAChR [47] [48] [49] 23 , demonstrating a dose response to Aβ 1-42 concentration and modulation of uptake by α7nAChR agonist, antagonists, and PAMs. Comparison of the CHRFAM7A null (0 copy) and heterozygous (1 copy) lines and transfection of CHRFAM7A into the null line demonstrated a regulatory effect of CHRFAM7A on Aβ 1-42 uptake, which was concentration dependent. Linear uptake of Aβ was observed in the 0 line, while the presence of CHRFAM7A mitigated the dose response of Aβ 1-42 uptake at higher concentrations, suggesting a protective effect beyond physiological concentrations. These observations align with the age-dependent penetrance of AD and the hypothesis of decreased clearance being the leading mechanism in sporadic AD 50 . We hypothesize that CHRFAM7A is protective in AD during the accumulation of Aβ 1-42 by mitigating Aβ 1-42 uptake and by activating neuronal IL-1β expression and release as cry for help. Since α7nAChR targeting clinical trials focused on synaptic modulation and cognitive benefit in the short term (12-14 weeks), its suggested diseasemodifying effect has not been explored.
These results suggest a negative modulatory effect of CHRFAM7A on synaptic transmission (relevance in schizophrenia) and a modulatory effect on Aβ 1-42 uptake (relevance in AD), consistent with the direction of the association signals in schizophrenia (increased CHRFAM7A as risk) and AD (loss of CHRFAM7A as risk). Since the CNV is frequent, lead optimization may identify more potent molecules when the screen has a model with CHRFAM7A. Pharmacogenetics needs to be implemented in the clinical trials as the presence of CHRFAM7A will likely have an impact on drug effect. Further studies are needed to evaluate whether there is a dosage effect of CHRFAM7A when present on both chromosomes, and even three copy individuals have been detected. Cell lines with the inverted copy of CHRFAM7A could answer the long lingering question whether the inverted copy is expressed and have a functional effect on the α7nAChR or if it behaves as a null allele. Isogenic lines can eliminate the genetic heterogeneity concern and are being developed. Using a genetically relevant model system and translating it into a genetically characterized population could result in markedly improved signal and is consistent with the efforts to deliver precision medicine.
